November 10, 2016 News by Charles Moore Canadian Firm Opens Clinics to Train People Using Its Keeogo Walking Assistance Device B-TemiaĀ announced the launch of its “b-Klinic Mobility” business unit, offering clinical services, information, training, and ongoing support to patients and healthcare professionalsĀ who use the company’s Keeogo walking assistive device. Keeogo is B-Temia’s first product in the class of dermoskeletons, designed to assist persons with mobility-related challenges that limit…
September 9, 2016 News by Patricia Silva, PhD 5 Canadians Studying for Future in Multiple Sclerosis Research Awarded Scholarships The Multiple Sclerosis Society of Canada (MSSC)Ā recently announced thatĀ five university students ā either diagnosed with or affected byĀ multiple sclerosis (MS)Ā āĀ were theĀ 2016 recipients of scholarships worth up toĀ $350,000 inĀ tuition and other school-related expenses. All five winnersĀ will receive the support throughout the four years of their undergraduate degrees, which are…
August 29, 2016 News by Patricia Silva, PhD Lemtrada to Treat Relapsing MS Now Part of New Brunswick, Canada, Drug Program The Government ofĀ New Brunswick added Ā Lemtrada (alemtuzumab), byĀ Sanofi Genzyme,Ā to the New Brunswick Prescription Drug Program (NBPDP) through special authorization for eligibleĀ patients with relapsing-remitting multiple sclerosis (RRMS). New BrunswickĀ joins other Canadian provinces, includingĀ Ontario, Saskatchewan,Ā Quebec, and Manitoba, in making this treatment available to RRMS patients, ages 18 andĀ older,Ā who have had…
August 26, 2016 News by Patricia Silva, PhD 900 Cyclists to Raise Money for MS in Biking Event in Quebec This Weekend The Quebec Division of the Multiple Sclerosis Society of Canada (MSSC)Ā announced that this year’sĀ 27th Medavie Blue Cross MS Bike, a fundraising bike ride on roads alongside St. Lawrence River, will take place Aug. 27 and 28Ā in the Mauricie region. A total of 900 cyclists are setĀ toĀ participate in…
August 25, 2016 News by Patricia Silva, PhD Teva’s New Copaxone Formulation for RRMS Approved by Health Canada Health Canada has approved Teva Canada Innovation‘sĀ three-time weekly 40 mg/mL injection of Copaxone (glatiramer acetate) that allows less frequent dosing forĀ patients with relapsing-remitting multiple sclerosis (RRMS). The approval wasĀ grounded primarily on data resulting from the Phase 3 Glatiramer Acetate Low-Frequency Administration (GALA) study, the largest Copaxone clinical…
July 26, 2016 Columns by admin ‘I am Cured,’ Says Woman with Aggressive Form of MS After Receiving HSCT in Canada An entry in the comments section of Multiple Sclerosis News Today caught my attention a couple of weeks ago, and peaked my interest. It was a personal tale of one woman’sĀ journeyĀ from beingĀ paralyzedĀ and told that her condition was “between you and God” to being able to walk again, thanks to HSCT.
May 27, 2016 News by Margarida Azevedo, MSc Report Highlights Series of Changes Needed from Canadian Employers and Government to Improve MS Patients’ Lives A new report by the Conference Board of CanadaāsĀ Canadian Alliance for Sustainable Health Care (CASHC)Ā notesĀ that employers and the Canadian government are not giving enough support towardsĀ increasing workforce participation among patients with multiple sclerosis (MS), despite the clear benefits such support would mean to not only the well-being of individuals…
December 29, 2015 News by Patricia Silva, PhD MS Patients Are Adequately, But Not Optimally, Treated for Depression A new Canadian study, published in the International Journal of MS Care, has concluded that the majority of patients with concurrent multiple sclerosis (MS) and depression are receiving antidepressant treatment. Despite this, however, many of these patients continue to report depressive symptoms. MS and depression co-occurrence is…
June 26, 2015 News by Charles Moore Health Canada Non-Insured Health Benefits Program Approves AUBAGIO for Relapsing Remitting Multiple Sclerosis Genzyme Canada has announced that Health Canada has approved its 14 mg dose of AUBAGIO as an expedited exception benefit product through the federal health regulator’s Non-Insured Health Benefits (NIHB) Program for eligible First Nations people and Inuit as a first-line oral tablet therapy for relapsing remitting multiple sclerosis (RRMS).
June 23, 2015 News by Patricia Silva, PhD Canadian Drug Expert Committee Recommends MS Therapy LEMTRADA For Public Coverage The Canadian Drug Expert Committee (CDEC) recently recommended thatĀ LEMTRADAĀ (alemtuzumab) beĀ included in provincial and other public drug plansĀ for the management of adult patients with relapsing-remitting multiple sclerosis (RRMS). The recommendation was madeĀ through Canada’sĀ Common Drug Review (CDR) and announced in a press releaseĀ by the company that…
May 26, 2015 News by Patricia Silva, PhD AUBAGIO Included in Prince Edward Island Pharmacare Canadian province Prince Edward Island (PEI) has approved the inclusion of Aubagio (teriflunomide) 14 mg in the PEI Pharmacare’s provincial drug formulary. This means that the drug developed and commercialized byĀ Genzyme is now financially supported by the state as aĀ first-line oral tablet to treat patients who…
December 2, 2014 News by Patricia Silva, PhD Aubagio for Relapsing-Remitting MS Now Funded in Alberta Genzyme, a Sanofi company with over 30 years of dedication to researching and developing novel treatments for rare and orphan diseases, has just announced the Alberta Drug Program has finally decided to include AubagioĀ® (teriflunomide) 14mg in the provincial drug formulary, indicated for the first-line…
September 24, 2014 News by Patricia Silva, PhD Multiple Sclerosis Summit in Quebec to Feature “Deepelling” As Encouragement for Active MS Lifestyles Deepelling International conferences on multiple sclerosis (MS) typically gather the most accomplished experts and leading biotech companies under one roof to exchange discoveries and celebrate new hope for MS patients all over the world. Quebec is one of North America’s epicenters for MS research and developments. This year, on…